The 2024 American Society of Clinical Oncology (ASCO) annual meeting, held May 30 to June 3 in Chicago, highlighted important advances in treatment across a broad spectrum of malignancies. Here, Editor-in-Chief Dr. William Gradishar reviews key trials in breast cancer.
postMONARCH Trial
The presentation of the industry-sponsored, phase 3 postMONARCH trial highlighted another treatment option for patients who develop progressive disease after being on a CDK4/6 inhibitor (CDK4/6i) in the metastatic setting (abstract LBA1001). For these patients, next-generation sequencing is usually performed at first recurrence to determine if there are any actionable mutations, such as PIK3CA or ESR1 mutations. Elacestrant is FDA-approved for patients with ES…
Author
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)